Ribosomal Protein S3 (RPS3), an Essential Component of NF-kappaB is a Novel and Selective Drug Target
Description of Invention:
NF-kappaB, represented by the p50-p65 heterodimer, is a DNA binding protein complex that has well documented functions in inflammatory or autoimmune diseases. Its potential as a drug target is currently being explored by the pharmaceutical industry.
The present invention describes that ribosomal protein S3 (RPS3) is a novel component of the p65 homodimer and p65-p50 heterodimer DNA binding complex. Experiments confirmed that RPS3 is essential for normal expression of specific NF-kappaB target genes, including key physiological events that require p65.
Advantages and Applications:
A novel and selective target for drug candidates targeting the NF-kappaB pathway.
Development Status:
The technology is currently in the pre-clinical stage of development.
Licensing Status: Available for exclusive and non-exclusive licensing.
Collaborative Research Opportunity:
The NIAID Laboratory of Immunology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact Dr. Michael Lenardo at 301-496-6754 for more information.
